<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04445051</url>
  </required_header>
  <id_info>
    <org_study_id>CP322</org_study_id>
    <nct_id>NCT04445051</nct_id>
  </id_info>
  <brief_title>Investigation of New Intermittent Catheters in Healthy Volunteers</brief_title>
  <official_title>Exploratory Investigation on Performance and Safety of New Intermittent Catheters in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of non-CE marked intermittent catheters. The study is a randomized, single
      blinded, cross-over investigation comparing two new catheters with a comparator catheter in
      30 adult healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CP322 study is an investigation of non-CE marked intermittent catheters which will be
      conducted in Denmark. The study is a randomized, single blinded, cross-over investigation
      comparing two new catheters with a comparator catheter in 30 adult healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Residual urine at 1st clogging</measure>
    <time_frame>Immediately after procedure/catherterization</time_frame>
    <description>Volume of residual urine at 1st clogging assessed by a pressure sensor with time-logged weighing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual urine post catheterisation</measure>
    <time_frame>Immediately after procedure/catherterization</time_frame>
    <description>Volume of residual urine post catheterization assessed by ultrasound scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discomfort</measure>
    <time_frame>Immediately after procedure/catherterization and Immediately after first normal voiding after procedure/catherterization.</time_frame>
    <description>Discomfort measured using Visual Analogue Scale (VAS). A tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain/discomfort is a straight line of 10 cm with one end meaning no pain/discomfort and the other end meaning the worst pain/discomfort imaginable. The subject marks a point on the line that matches the amount of pain/discomfort he or she feels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Retention, Urinary</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SpeediCath® standard Male and Female</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New intermittent catheter variation 1 for male and female</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New intermittent catheter variation 1 for male and female</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New intermittent catheter variation 2 for male and female</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New intermittent catheter variation 2 for male and female</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New intermittent catheters variation 1 and 2 for both male and females</intervention_name>
    <description>The new catheters are not named at this point but are intended for intermittent drainage of the bladder.</description>
    <arm_group_label>New intermittent catheter variation 1 for male and female</arm_group_label>
    <arm_group_label>New intermittent catheter variation 2 for male and female</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is at least 18 years of age and has full legal capacity

          2. Has given written informed consent and signed letter of authority and secrecy
             agreement

          3. Willing to comply with not using analgesics1 up to 24 hours prior to catheterisation
             visits

          4. Negative urine multistix - erythrocytes (haematuria)

        Exclusion Criteria:

          1. Participation in any other clinical investigations during this investigation

          2. Known hypersensitivity towards any of the test products

          3. Symptoms of urinary tract infections (UTIs) (Investigators judgement)

          4. Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Bagi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blegdamsvej 9, Urologisk klinik Afsnit 2112, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanne L. Gotfredsen, PhD</last_name>
    <phone>+4549113350</phone>
    <email>dkjoat@coloplast.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stine Haandbæk Sommersdahl</last_name>
    <phone>+4549113299</phone>
    <email>dksths@coloplast.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blegdamsvej 9, Urologisk klinik Afsnit 2112, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Copenhagen Ø</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Bagi, MD</last_name>
      <phone>+45 35 45 21 11</phone>
      <email>Per.Bagi@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Rikke Permild</last_name>
      <phone>+45 35 45 21 11</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

